255 related articles for article (PubMed ID: 12086885)
21. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
22. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Gorre ME; Sawyers CL
Curr Opin Hematol; 2002 Jul; 9(4):303-7. PubMed ID: 12042704
[TBL] [Abstract][Full Text] [Related]
24. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
25. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
27. STI571 as a targeted therapy for CML.
O'Dwyer ME; Mauro MJ; Druker BJ
Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
[TBL] [Abstract][Full Text] [Related]
28. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
[TBL] [Abstract][Full Text] [Related]
29. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
[No Abstract] [Full Text] [Related]
30. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
31. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
32. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
[No Abstract] [Full Text] [Related]
33. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
Mahon FX
Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
[TBL] [Abstract][Full Text] [Related]
34. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
[TBL] [Abstract][Full Text] [Related]
35. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
36. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
O'Dwyer ME; Druker BJ
Curr Opin Oncol; 2000 Nov; 12(6):594-7. PubMed ID: 11085460
[TBL] [Abstract][Full Text] [Related]
37. Decrease of resistance to imatinib in leukaemia.
Bakalova R; Zhelev Z; Ohba H
Lancet; 2002 May; 359(9319):1776-7. PubMed ID: 12049890
[No Abstract] [Full Text] [Related]
38. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
39. Is there a cloud in the silver lining for imatinib?
Paterson SC; Smith KD; Holyoake TL; Jørgensen HG
Br J Cancer; 2003 Apr; 88(7):983-7. PubMed ID: 12671692
[TBL] [Abstract][Full Text] [Related]
40. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]